Stockscreener 앱 받기
136.36
5.21%
6.75
시장 영업 전:
136.73
0.37
+0.27%
전일 마감가:
$129.61
열려 있는:
$132.62
하루 거래량:
9.17M
Relative Volume:
1.31
시가총액:
$169.30B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
18.55
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
+7.93%
1개월 성능:
+5.57%
6개월 성능:
+9.66%
1년 성능:
+21.99%
1일 변동 폭
$132.00
$136.60
1주일 범위
$125.12
$136.60
52주 변동 폭
$107.75
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
136.36 | 160.92B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,235.56 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.24 | 624.26B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.65 | 450.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.86 | 313.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.03 | 296.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
The Biktarvy from Gilead SciencesHIV combo tablet grows in US use - AD HOC NEWS
A Look at Gilead Sciences Inc (GILD) After 5.2% Gain -- GF Value $96.06 vs Price $136.36 - GuruFocus
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MSN
Gilead Sciences Inc Stock (GILD) Closed Up by 5.35% on Jul 7: What Signal Does It Send? - TradingKey
Gilead Sciences rises as analyst upgrade adds to HIV franchise momentum - Quiver Quantitative
Gilead Sciences keeps building its antiviral pipeline. The focus shifts to long-term growth and US m - AD HOC NEWS
Gilead Stock Rallies As Trodelvy Wins First-Line Cancer Nod - StocksToTrade
BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients - GlobeNewswire Inc.
Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 - marketscreener.com
Gilead price tries to pierce ceiling of descending correctional price channelForecast today07-07-2026 - Economies.com
RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating - marketscreener.com
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
GILDGilead Sciences Inc Options - Finviz
What's Going on With Gilead Sciences Stock Monday?Gilead Sciences (NASDAQ:GILD) - Benzinga
Gilead Sciences (GILD) Participates in Ebola Treatment Clinical Trial in Congo - GuruFocus
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More - Yahoo Finance
This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Gilead Sciences stock rating upgraded to Buy by HSBC on HIV outlook - Investing.com Canada
Gilead Sciences highlights its antiviral pipeline as investors watch long-term growth potential - AD HOC NEWS
Earnings call transcript: Gilead Sciences beats Q1 2026 forecasts, stock dips - Investing.com
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel - The National Law Review
Gilead Sciences stock faces a thin data day. Business focus stays intact. - AD HOC NEWS
Insider Sell: Daniel O'Day Sells 15,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update - marketscreener.com
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Sahm
Gilead Sciences Inc (GILD) Stock Up 4.2% but GF Value Says Overv - GuruFocus
Gilead (NASDAQ: GILD) CEO sells 15,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Calvert VP SRI Balanced Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says - Law360
Gilead Sciences highlights its antiviral portfolio as a long-term growth driver - AD HOC NEWS
List of 21 Acquisitions by Gilead (Jul 2026) - Tracxn
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $168 - Moomoo
Gilead Sciences consensus picture, shares steady on NASDAQ - AD HOC NEWS
Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - WSJ
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector - ChartMill
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell Top 200 Growth Benchmark - marketscreener.com
Gilead Sciences wins Trodelvy approvals, shares supported by oncology focus - AD HOC NEWS
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 1000 Dynamic Index - marketscreener.com
Gilead Sciences launches Trodelvy in TNBC, shares hold near $128 - AD HOC NEWS
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC - Insider Monkey
Price to sales forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences Raises Guidance After Results Top Views - WSJ
Enterprise value to revenue forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Enterprise value to EBITDA forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences clears a fresh 12?month high, shares react to new FDA approval - AD HOC NEWS
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative? - Yahoo Finance
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
자본화:
|
볼륨(24시간):